ES2180751T3 - Inhibidor de metastasis de cancer. - Google Patents

Inhibidor de metastasis de cancer.

Info

Publication number
ES2180751T3
ES2180751T3 ES96909329T ES96909329T ES2180751T3 ES 2180751 T3 ES2180751 T3 ES 2180751T3 ES 96909329 T ES96909329 T ES 96909329T ES 96909329 T ES96909329 T ES 96909329T ES 2180751 T3 ES2180751 T3 ES 2180751T3
Authority
ES
Spain
Prior art keywords
sub
cancerose
represent
metastasis
benzoic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96909329T
Other languages
English (en)
Inventor
Jiro Shibata
Konstanty Wierzba
Koji Murakami
Yuji Yamada
Koichi Shudo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2180751T3 publication Critical patent/ES2180751T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

INHIBIDOR DE LA METASTASIS CANCEROSA QUE INCLUYE UN DERIVADO DE ACIDO BENZOICO QUE SE REPRESENTA POR LA FORMULA GENERAL (I) Y TIENE UN EFECTO INHIBITORIO DE LA METASTASIS CANCEROSA EXCELENTE Y SUBRAYABLE COMO INGREDIENTE ACTIVO; EL USO DE DERIVADOS DE ACIDO BENZOICO PARA PRODUCIR EL INHIBIDOR DE LA METASTASIS CANCEROSA; Y UN METODO PARA INHIBIR LA METASTASIS CANCEROSA MEDIANTE LA ADMINISTRACION DE UNA CANTIDAD EFECTIVA DEL DERIVADO DE ACIDO BENZOICO A MAMIFEROS. EN DICHA FORMULA (I), R{SUB,1},R{SUB,2},R{SUB,3} Y R{SUB,4) PUEDEN SER LO MISMO O DIFERENTES Y REPRESENTAR CADA UNO HIDROGENO, HIDROXI O TRIMETILSILIL, O ALTERNATIVAMENTE R{SUB,3}, R{SUB,4} SE UNEN MUTUAMENTE PARA REPRESENTAR TETRAMETILENO SUSTITUTIVO DE ALQUIL INFERIOR; Y X REPRESENTA -COCH=C(OH)-, -NHCO-O-CONH-, QUE SE PROPORCIONA CUANDO R{SUB,3} Y R{SUB,4} SE UNEN MUTUAMENTE PARA REPRESENTAR TETRAMETILENO DE SUSTITUTIVO DE ALQUIL INFERIOR, X REPRESENTA -COCH=C(OH)-O- CONH-.
ES96909329T 1995-04-10 1996-04-10 Inhibidor de metastasis de cancer. Expired - Lifetime ES2180751T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8380395 1995-04-10

Publications (1)

Publication Number Publication Date
ES2180751T3 true ES2180751T3 (es) 2003-02-16

Family

ID=13812829

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96909329T Expired - Lifetime ES2180751T3 (es) 1995-04-10 1996-04-10 Inhibidor de metastasis de cancer.

Country Status (12)

Country Link
US (1) US5750515A (es)
EP (1) EP0768084B1 (es)
JP (1) JP3208437B2 (es)
KR (1) KR100207356B1 (es)
AT (1) ATE223713T1 (es)
AU (1) AU693682B2 (es)
CA (1) CA2191850C (es)
DE (1) DE69623555T2 (es)
DK (1) DK0768084T3 (es)
ES (1) ES2180751T3 (es)
PT (1) PT768084E (es)
WO (1) WO1996032101A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008204A (en) 1995-09-01 1999-12-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5965606A (en) * 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
KR20010063274A (ko) * 1999-12-22 2001-07-09 성재갑 〔1-｛〔1-（1,3-벤조디옥솔-5-일메틸-1ｈ-이미다졸-5-일〕메틸｝-4-(1-나프틸)-1ｈ-피롤-3-일〕（4-메틸-1-피페라지닐）메타논의 약학적 조성물
NO20003591L (no) * 2000-07-13 2002-01-14 Thia Medica As Fettsyreanaloger for behandling av kreft
ES2316471T3 (es) 2000-10-02 2009-04-16 F. Hoffmann-La Roche Ag Retinoides para el tratamiento del efisema.
US8198328B2 (en) * 2004-01-21 2012-06-12 New York University Treatment of cancer using benzoic acid derivatives
US20050202055A1 (en) * 2004-03-11 2005-09-15 Koichi Shudo, Tokyo, Japan Anti-wrinkle agent
US8415315B2 (en) 2004-05-06 2013-04-09 University Of Central Florida Research Foundation, Inc. Methods and compositions for inhibiting the proliferation of cancer cells
AU2006221479B2 (en) * 2005-03-08 2011-04-21 Taiho Pharmaceutical Co., Ltd. Method of treating liver cancer
CA2626879A1 (en) * 2005-10-24 2007-05-03 Taiho Pharmaceutical Co., Ltd. Method for predicting efficacy of rar-.alpha. agonist
TW200922554A (en) * 2007-10-11 2009-06-01 Taiho Pharmaceutical Co Ltd Bis(trimethylsilyl)phenyl compound or salt thereof, and use thereof
GB0915196D0 (en) 2009-09-01 2009-10-07 King S College London Therapeutic compounds and their use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5513238A (en) * 1978-07-17 1980-01-30 Banyu Pharmaceut Co Ltd Novel compound having immunoactivating action, its preparation and application
JP2752630B2 (ja) * 1988-03-29 1998-05-18 大鵬薬品工業株式会社 新規安息香酸誘導体及びその製造方法
JP2761023B2 (ja) * 1989-03-20 1998-06-04 大鵬薬品工業株式会社 新規安息香酸誘導体及びその製造方法
JPH0366647A (ja) * 1989-08-03 1991-03-22 Koichi Shudo フェニルベンゾエート誘導体
JPH03115289A (ja) * 1989-09-28 1991-05-16 Koichi Shudo 新規安息香酸誘導体、その製造方法及びその用途
JP3650144B2 (ja) * 1994-06-08 2005-05-18 花王株式会社 細胞接着抑制剤

Also Published As

Publication number Publication date
EP0768084A1 (en) 1997-04-16
PT768084E (pt) 2002-12-31
US5750515A (en) 1998-05-12
JP3208437B2 (ja) 2001-09-10
EP0768084B1 (en) 2002-09-11
DE69623555T2 (de) 2003-05-15
AU5287596A (en) 1996-10-30
KR970703761A (ko) 1997-08-09
WO1996032101A1 (fr) 1996-10-17
KR100207356B1 (ko) 1999-07-15
DK0768084T3 (da) 2002-10-14
ATE223713T1 (de) 2002-09-15
CA2191850C (en) 2002-06-18
DE69623555D1 (de) 2002-10-17
CA2191850A1 (en) 1996-10-17
AU693682B2 (en) 1998-07-02
EP0768084A4 (en) 1999-05-06

Similar Documents

Publication Publication Date Title
ES2180751T3 (es) Inhibidor de metastasis de cancer.
MX9202328A (es) Composicion farmaceutica local que contiene un compuesto alilamina como el agente activo.
AR035482A1 (es) Uso de un compuesto de cianoquinolina para la manufactura de un medicamento para tratar o inhibir polipos colonicos
CO5690566A2 (es) Metodo para inhibir la produccion de lipoproteina remanente
NO954400L (no) Substituerte pyrrolidin-3-yl-alkyl-piperidiner som er anvendbare som tachykininantagonister
UY26285A1 (es) Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
ES2164920T3 (es) Nuevos derivados heterociclicos y uso medicinal de los mismos.
NO950757L (no) Antitussiv
ES2101449T3 (es) Inhibicion de la seborrea y el acne.
ES2172937T3 (es) 21-hidroxi-6,19-oxidoprogesterona(21oh-6op) como medicamento para tratar el exceso de glucocorticoides.
ATE287267T1 (de) Kombinationstherapien mit gefässschädigender aktivität
NO985964D0 (no) Administrasjonskur for H+, K+ -ATPase-inhibitorer
AR012217A1 (es) Una composicion topica para mejorar la penetracion de compuestos farmaceuticos
UY26678A1 (es) El uso de composiciones a base de antibióticos de azalidos para tratar o prevenir una infección bacteriana o protozoaria en mamíferos
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
AR003137A1 (es) Una composicion farmaceutica para tratar la leucemia
AR004474A1 (es) Compuestos de 10-aminoalifatil-dibenz [b,f]oxepinas antineurodegenerativamente activas, utiles para el tratamiento de estados neurodegenerativos y composiciones farmaceuticas que los contienen
NO985679D0 (no) Dihydrobenzopyran og beslektede forbindelser nyttige som anti-inflammasjonsmidler
DK1109560T3 (da) Som AICARFT-inhibitorer anvendelige forbindelser
TR200102514T2 (tr) COPD tedavisi için metod
AR047880A1 (es) COMBINACIoN DE UN INHIBIDOR DE RENINA Y DIURÉTICOS
ES2161439T3 (es) Derivados triterpenicos medicamentos para enfermedades hepaticas.
ES2124280T3 (es) O-fenilendiaminas que contienen grupos fluoralquil(eno) y su empleo como compuestos intermedios en la sintesis de benzimidazoles.
IT1265647B1 (it) Composizione farmaceutiche topiche per le allergie respiratorie
AR004029A1 (es) Nuevas formulaciones farmaceuticas